These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 385579)

  • 1. In vitro susceptibility of urinary isolates of Escherichia coli to cinoxacin.
    Barnham M; Gaya H
    J Antimicrob Chemother; 1979 Jul; 5(4):413-8. PubMed ID: 385579
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on cinoxacin. 1. In vitro activity of cinoxacin, as compared to nalidixic acid, against urinary tract pathogens.
    Mårdh PA; Collen S; Andersson KE
    J Antimicrob Chemother; 1977 Sep; 3(5):411-6. PubMed ID: 903323
    [No Abstract]   [Full Text] [Related]  

  • 3. ["In vitro" and "in vivo" antibacterial activity of a new synthetic antibiotic cinoxacin].
    Ravagnan G; Piccolomini R
    Boll Soc Ital Biol Sper; 1979 Jul; 55(14):1348-54. PubMed ID: 391252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinoxacin: in vitro antibacterial studies of a new synthetic organic acid.
    Lumish RM; Norden CW
    Antimicrob Agents Chemother; 1975 Feb; 7(2):159-63. PubMed ID: 1094949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro synergistic activity of some chinolinic compounds combined with beta-lactam antibiotics against gram-positive and gram-negative clinical isolates.
    Ravagnan G; Piccolomini R; Speciale AM; Russo G; Renzini G
    Chemotherapy; 1985; 31(3):191-9. PubMed ID: 3996087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antimicrobial activity of cinoxacin against 2,968 clinical bacterial isolates.
    Jones RN; Fuchs PC
    Antimicrob Agents Chemother; 1976 Jul; 10(1):146-9. PubMed ID: 984747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical comparison of cinoxacin and nalidixic acid in the treatment of urinary tract infection.
    Bucy JG
    J Urol; 1981 Jun; 125(6):822-4. PubMed ID: 7017171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of increase in resistance to quinolones in general practice isolates of Escherichia coli.
    Weber P; Plaisance JJ; Mancy C
    J Antimicrob Chemother; 1994 Jul; 34(1):187-8. PubMed ID: 7961211
    [No Abstract]   [Full Text] [Related]  

  • 9. Cinoxacin: mechanism of action, spectrum of activity, pharmacokinetics, adverse reactions, and therapeutic indications.
    Scavone JM; Gleckman RA; Fraser DG
    Pharmacotherapy; 1982; 2(5):266-72. PubMed ID: 6763208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of nalidixic acid, pipemidic acid and cinoxacin on chondrocyte metabolism in explants of articular cartilage.
    Brand HS; van Kampen GP; van der Korst JK
    Clin Exp Rheumatol; 1990; 8(4):393-5. PubMed ID: 2397627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibacterial activity of cinoxacin in vitro.
    Giamarellou H; Jackson GG
    Antimicrob Agents Chemother; 1975 May; 7(5):688-92. PubMed ID: 1096811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative evaluation of norfloxacin and cinoxacin in the therapy of complicated infections of the urinary tract].
    Cristiano P; Morelli G; Simioli F; Iovene MR; Della Vittoria Scarpati M; Manguso L
    Minerva Med; 1989 Apr; 80(4):393-5. PubMed ID: 2657499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinoxacin and nalidixic acid in treatment of urinary tract infections.
    Drylie DM
    Urology; 1981 May; 17(5):500-1. PubMed ID: 7233672
    [No Abstract]   [Full Text] [Related]  

  • 14. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
    Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
    Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phylogenetic background and carriage of pathogenicity island-like domains in relation to antibiotic resistance profiles among Escherichia coli urosepsis isolates.
    Houdouin V; Bonacorsi S; Bidet P; Bingen-Bidois M; Barraud D; Bingen E
    J Antimicrob Chemother; 2006 Oct; 58(4):748-51. PubMed ID: 16905527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escherichia coli in urinary tract infections in Sudanese patients.
    Erwa HH
    Trop Geogr Med; 1972 Jan; 24(1):60-5. PubMed ID: 4551336
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.
    Vuye A
    Arzneimittelforschung; 1983; 33(12):1623-7. PubMed ID: 6230083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility testing of Escherichia coli isolates from urines: are we at risk of reporting false antibiotic resistance to co-amoxiclav?
    Bond A; Plumb H; Turner P
    J Antimicrob Chemother; 2012 Jun; 67(6):1557-8. PubMed ID: 22334608
    [No Abstract]   [Full Text] [Related]  

  • 19. [Occurrence of enteropathogenic serotypes of Escherichia coli in urinary tract infections].
    Schmid E; Sonnabend W
    Pathol Microbiol (Basel); 1973; 39(5):348-57. PubMed ID: 4580715
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of cinoxacin on the conjugal transfer of R-plasmids in Escherichia coli.
    Vuye A
    J Pharm Belg; 1980; 62(6):451-5. PubMed ID: 7007611
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.